New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
06:33 EDTALXNAlexion raises FY14 EPS view to $4.37-$4.47 from $3.70-$3.80, consensus $3.89
Raises FY14 net product revenue guidance to $2.15B-$2.17B from $2B-$2.02B, consensus $2.03B.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
07:06 EDTALXNAlexion backs FY15 non-GAAP EPS view of $4.70-$4.80, consensus $4.85
Backs FY15 revenue view of $2.6B-$2.62B, consensus $2.63B.
07:01 EDTALXNAlexion receives notification of PDUFA date extension for Kanuma
Subscribe for More Information
September 2, 2015
07:53 EDTALXNFDA PDUFA Date for Alexion's Asfotase Alfa is September 2, 2015
Subscribe for More Information
September 1, 2015
17:57 EDTALXNAlexion CEO sees slow sales uptake for Kanuma, Strensiq, Reuters says
In a Reuters interview following EU approval of the company's Strensiq and Kanuma treatments, Alexion CEO David Hallal said he expects a slow sales uptake for the two drugs, adding that boosting disease awareness and finding patients is a challenge. "It takes time to reach the patients and the physicians. When we launch, it's usually one patient at a time," said Hallal. The CEO also remarked that the company is targeting similar pricing between the U.S. and elsewhere. Reference Link
05:39 EDTALXNAlexion granted marketing authorization for Kanuma in EU
Subscribe for More Information
05:38 EDTALXNAlexion granted marketing authorization for Strensiq in EU
Subscribe for More Information
August 31, 2015
19:28 EDTALXNAlexion initiated with a Strong Buy at Raymond James
Target $225.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use